Tiger Brokers

BUZZ-ImmunityBio rises as cancer drug therapy sales surge, global approvals expand

Reuters
Feb 23
BUZZ-ImmunityBio rises as cancer drug therapy sales surge, global approvals expand

** Shares of drug developer ImmunityBio IBRX.O up 1.3% at $8.61 premarket

** Co says sales of its cancer therapy Anktiva surged in 2025, with net product revenue up 700% to $113 mln

** Anktiva is approved for bladder cancer, a disease where abnormal cell growth affects the urinary bladder

** Co says drug now approved in 33 countries; Saudi Arabia also cleared Anktiva for lung cancer in Jan, with launch expected within two months

** Shares down ~23% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10